One patient in the study died of a severe case of cytokine storm, an immune reaction often associated with CAR-T treatment. Overall, moderate to severe cytokine storms were reported in less than 6% of patients. Three percent of patients reported high-grade neurotoxicity, another side effect often seen in CAR-T therapy.
The study was published in the New England Journal of Medicine in February.
– CAR-T cell therapies have shown a groundbreaking potential for the treatment of blood cancer. We are proud to be able to offer the first CAR-T cell therapy to multiple myeloma patients who have undergone several treatment lines, which provides the opportunity for long-term effect, says Samit Hirawat who is Bristol Myers Squibb’s chief physician.
Get the latest news delivered to your inbox
Follow us on social media networks